Abbott launches Lingo over-the-counter CGM in the US

Abbott has introduced Lingo, its first over-the-counter glucose sensor in the U.S., shortly after Dexcom launched its similar product. Lingo, priced at $49 for one 14-day sensor or $249 for six, is aimed at wellness users aged 18 and older who do not use insulin. It tracks how diet and exercise affect blood glucose levels, offering features like glucose readings, spike counts, and personalized recommendations through its app.

Dexcom's Stelo, a 15-day sensor, provides similar features and tracks time-in-range, and is also suitable for non-insulin users. Both companies are entering the OTC CGM market following FDA approval. Abbott plans to release another OTC sensor, Libre Rio, specifically for diabetics and is exploring additional biomarkers. Dexcom expects Stelo to generate $40 million in sales by the end of the year, as noted at the Wells Fargo 2024 Healthcare Conference.